The novel therapeutic development targeting KRAS-mutant cancers also works on discovery of pan-Kras inhibitors and proteolysis targeting chimeras (PROTAC) which avoid HRAS and NRAS [55,56]. The gene discussed is KRAS; the disease is cancer.